home / stock / hepa / hepa news

HEPA News and Press, Hepion Pharmaceuticals Inc. From 11/16/21

Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...
HEPA - Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
HEPA - Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

HEPA - Anti-Cancer Mechanism of Hepion Pharmaceuticals' CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

HEPA - Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- EquitiesIQ announced today that the EquitiesIQ Q4 2021 Investor Forum presentation, a virtual investor event series featuring Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D., Chief Executive Officer of Hepion Pharmaceuticals (NASDAQ: HEPA), has been...
HEPA - Hepion Pharmaceuticals to Present at the EquitiesIQ Q4 2021 Investor Forum

NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- EquitiesIQ announced today that Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D., Chief Executive Officer of Hepion Pharmaceuticals (NASDAQ: HEPA), will present at the EquitiesIQ Q4 2021 Investor Forum, a virtual investor event series. Dr. Foster...

HEPA - Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

HEPA - All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431

EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...
HEPA - Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial." The main data reported by the company was the % reduction of the Pro-C3 biomarker in serum. According to my estimate, CRV431 would be the candidate drug with the greates...

HEPA - UEC, HEPA and YPF among pre market gainers

Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...

HEPA - Additional Data from Hepion Pharmaceuticals' Phase 2a 'AMBITION' Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b 'ASCEND-NASH' Clinical Program

Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431 PK-PD models successfully predict early reductions in Pro-C3 and ALT Hepion’s proprietary AI-POWR™ and machine learning accurately predict CRV431 responders Anti...
Previous 10 Next 10